Summary
AbbVie Inc. reported strong financial performance for the fiscal year ended December 31, 2019, with net revenues reaching $33.3 billion, a 1.6% increase year-over-year, driven by its key pharmaceutical products. The company's strategic focus remains on innovation, pipeline advancement, and returning value to shareholders through dividends and share repurchases. A significant development during the year was the announcement of AbbVie's definitive agreement to acquire Allergan plc for approximately $63 billion, a transaction expected to diversify AbbVie's portfolio and create a leading biopharmaceutical company with strong positions across multiple therapeutic areas. The company highlighted growth from key products like IMBRUVICA and VENCLEXTA, along with continued strength in HUMIRA in the U.S. and the launches of SKYRIZI and RINVOQ. However, AbbVie faced international HUMIRA biosimilar competition which impacted overseas sales. The company is actively managing this and anticipates no direct biosimilar competition for HUMIRA in the U.S. until 2023. AbbVie's robust pipeline continues to be a key focus, with numerous compounds in clinical development, particularly in immunology, oncology, and neuroscience. Key financial metrics for 2019 included operating earnings of $13.0 billion and diluted earnings per share of $5.28. The company also continued its commitment to shareholder returns, increasing its quarterly cash dividend by approximately 10.3%. Despite challenges such as biosimilar competition and the significant debt financing for the Allergan acquisition, AbbVie's strategic positioning and diversified product portfolio suggest a resilient outlook for future growth.
Financial Highlights
56 data points| Revenue | $33.27B |
| Cost of Revenue | $7.44B |
| Gross Profit | $25.83B |
| SG&A Expenses | $6.94B |
| Operating Expenses | $20.28B |
| Operating Income | $12.98B |
| Interest Expense | $1.78B |
| Net Income | $7.88B |
| EPS (Basic) | $5.30 |
| EPS (Diluted) | $5.28 |
| Shares Outstanding (Basic) | 1.48B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1AbbVie announced a definitive agreement to acquire Allergan plc for approximately $63 billion, a move aimed at diversifying its product portfolio and therapeutic areas.
- 2Net revenues grew to $33.3 billion, a 1.6% increase year-over-year, primarily driven by strong U.S. sales of HUMIRA and growth from IMBRUVICA and VENCLEXTA.
- 3New immunology products SKYRIZI and RINVOQ, launched in 2019, contributed $355 million and $47 million in net revenues, respectively.
- 4International HUMIRA sales declined by 28% due to biosimilar competition, while U.S. HUMIRA sales grew by 9%.
- 5The company's R&D expenses decreased in 2019 to $6.4 billion, partly due to significant impairment charges related to Rova-T in prior years.
- 6AbbVie continued its commitment to returning value to shareholders with a 10.3% increase in its quarterly cash dividend.
- 7The company's significant debt financing for the Allergan acquisition resulted in a substantial increase in long-term debt, reaching $66.7 billion by year-end 2019.